Loratadine in treating irritable bowel syndrome

Clinical efficacy and safety of loratadine in treating irritable bowel syndrome with predominant diarrhea

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20201221049782N1

Enrollment

100

Registered

2021-04-16

Start date

2021-02-28

Completion date

Unknown

Last updated

2022-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Irritable bowel syndrome with diarrhea. Irritable bowel syndrome with diarrhea

Interventions

Intervention 1: Intervention group: The patients in the Loratadine group receive Loratadine tablets(10mg, oral) made by Pharmachemie pharmaceutical company once daily for 4-6 weeks (if patients do not

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: Patients with IBS-D Age between 18 and 65 No abnormalities on physical examination Routine CBC No abnormalities observed by Sigmoidoscopy Normal thyroid function Negative routine stool examinations

Exclusion criteria

Exclusion criteria: Diabetes Renal impairment Cardiovascular disorders Psychiatric disorders Colitis Celiac disease Use of drugs that affect the digestive system Use of Analgesics Use of Antihistamines Loratadine intolerance

Design outcomes

Primary

Measure	Time frame
Diarrhea Frequency. Timepoint: before treatment and 14, 28, 42 and 56 days after beginning of treatment. Method of measurement: questionnaire.;Severity of pain. Timepoint: before treatment and 14, 28, 42 and 56 days after beginning of treatment. Method of measurement: questionnaire.;Abdominal pain frequency. Timepoint: before treatment and 14, 28, 42 and 56 days after beginning of treatment. Method of measurement: questionnaire.;Defecation urgency. Timepoint: before treatment and 14, 28, 42 and 56 days after beginning of treatment. Method of measurement: questionnaire.;Bloating. Timepoint: before treatment and 14, 28, 42 and 56 days after beginning of treatment. Method of measurement: questionnaire.	—

Measure

Time frame

Diarrhea Frequency. Timepoint: before treatment and 14, 28, 42 and 56 days after beginning of treatment. Method of measurement: questionnaire.;Severity of pain. Timepoint: before treatment and 14, 28, 42 and 56 days after beginning of treatment. Method of measurement: questionnaire.;Abdominal pain frequency. Timepoint: before treatment and 14, 28, 42 and 56 days after beginning of treatment. Method of measurement: questionnaire.;Defecation urgency. Timepoint: before treatment and 14, 28, 42 and 56 days after beginning of treatment. Method of measurement: questionnaire.;Bloating. Timepoint: before treatment and 14, 28, 42 and 56 days after beginning of treatment. Method of measurement: questionnaire.

—

Secondary

Measure	Time frame
Quality of life score. Timepoint: before treatment and 14, 28, 42 and 56 days after beginning of treatment. Method of measurement: Irritable bowel syndrome-Quality of life questionnaire(IBS-QOL).	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFatere seyedalipour

Babol University of Medical Sciences

f_seyedalipour@yahoo.com+98 11 3223 8301

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026